J&J launches new iteration of nursing campaign (J&J)

'Where would the world be with­out nurs­es?' J&J re­fresh­es cam­paign hon­or­ing health work­ers

More than two and a half years in­to the pan­dem­ic, John­son & John­son wants to re­mind peo­ple that nurs­es are much more than just care­givers.

In the lat­est it­er­a­tion of its cam­paign, J&J hon­ors nurs­es as “in­no­va­tors, life­savers, and fierce pa­tient ad­vo­cates.” The pro­gram got a re­fresh from last year, in­clud­ing a new tagline, “Where Would the World Be With­out Nurs­es,” and videos that de­buted on so­cial me­dia on Thurs­day.

“Who would be there when no one else is?” a nar­ra­tor asks in J&J’s 30-sec­ond ad video that de­picts nurs­es scrub­bing up, per­form­ing CPR and com­fort­ing pa­tients.

J&J claims it has been a “proud cham­pi­on of nurs­es since 1897,” and launched a cam­paign in 2001 to dri­ve more peo­ple in­to the pro­fes­sion with the help of TV ad spots, grants, schol­ar­ships and more. There have been sev­er­al it­er­a­tions since, in­clud­ing last year’s “Nurs­es Rise to the Chal­lenge Every Day” cam­paign.

Lyn­da Ben­ton

“Last year, we were just re­al­ly fo­cused on try­ing to en­gage and sup­port and re­mind nurs­es that we saw their val­ue,” said Lyn­da Ben­ton, se­nior di­rec­tor of glob­al com­mu­ni­ty im­pact strate­gic ini­tia­tives for J&J Nurs­ing. “Now we want to open the lens and get a broad­er health­care com­mu­ni­ty to un­der­stand what nurs­es bring to health­care.”

The ads are meant to ad­dress “alarm­ing lev­els of burnout” in the nurs­ing field, J&J said. A re­port pub­lished last year by the Amer­i­can As­so­ci­a­tion of Crit­i­cal-Care Nurs­es found that 66% of sur­veyed acute and crit­i­cal care nurs­es had con­sid­ered leav­ing their jobs be­cause of the pan­dem­ic. The Amer­i­can Nurs­es As­so­ci­a­tion al­so urged the HHS sec­re­tary in a let­ter last year to de­clare the nurse staffing short­age a na­tion­al cri­sis.

In 2022, health­care em­ploy­ment has in­creased at a sig­nif­i­cant­ly high­er month­ly rate than last year’s, ac­cord­ing to the Bu­reau of La­bor Sta­tis­tics. But there’s more to be done, J&J em­pha­sized.

“When you think about ear­ly 2020, the world was ba­si­cal­ly cheer­ing on the nurs­ing work­force and thank­ing them for all they were do­ing to care for pa­tients,” Ben­ton said. “As the pan­dem­ic wore on, and the vac­cines start­ed com­ing out … in some cas­es life went back to nor­mal and [peo­ple] kind of for­got about the nurs­es who were still work­ing in­side the walls of the hos­pi­tal and sav­ing lives on a day-to-day ba­sis.”

The lat­est cam­paign is com­ple­ment­ed by videos spot­light­ing the next gen­er­a­tion of nurs­es, and a ‘To­day” show seg­ment called “He­roes Among Us.”

“If we don’t ad­dress this, this is a health­care cri­sis for every­body,” Ben­ton said. “It’s just so im­por­tant that peo­ple will re­al­ly wake up and un­der­stand what’s hap­pen­ing to­day with­in the nurs­ing pro­fes­sion.”

Late Fri­day ap­proval; Trio of biotechs wind down; Stem cell pi­o­neer finds new fron­tier; Biotech icon to re­tire; and more

Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add Endpoints Weekly. New to Endpoints? Sign up here.

I hope your weekend is off to a nice start, wherever you are reading this email. As for me, I’m trying to catch the tail of the Lunar New Year festivities.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 157,500+ biopharma pros reading Endpoints daily — and it's free.

Pfiz­er lays off em­ploy­ees at Cal­i­for­nia and Con­necti­cut sites

Pfizer has laid off employees at its La Jolla, CA, and Groton, CT sites, according to multiple LinkedIn posts from former employees.

The Big Pharma confirmed to Endpoints News it has let go of some employees, but a spokesperson declined to specify how many workers were impacted and the exact locations affected. Earlier this month, the drug developer had confirmed to Endpoints it was sharpening its focus and doing away with some early research on areas such as rare disease, oncology and gene therapies.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Jake Van Naarden, Loxo@Lilly CEO

Lil­ly en­ters ripe BTK field with quick FDA nod in man­tle cell lym­phoma

Eli Lilly has succeeded in its attempt to get the first non-covalent version of Bruton’s tyrosine kinase, or BTK, inhibitors to market, pushing it past rival Merck.

The FDA gave an accelerated nod to Lilly’s daily oral med, to be sold as Jaypirca, for patients with relapsed or refractory mantle cell lymphoma.

The agency’s green light, disclosed by the Indianapolis Big Pharma on Friday afternoon, catapults Lilly into a field dominated by covalent BTK inhibitors, which includes AbbVie and Johnson & Johnson’s Imbruvica, AstraZeneca’s Calquence and BeiGene’s Brukinsa.

Filip Dubovsky, Novavax CMO

No­vavax gets ready to take an­oth­er shot at Covid vac­cine mar­ket with next sea­son plans

While mRNA took center stage at yesterday’s FDA vaccine advisory committee meeting, Novavax announced its plans to deliver an updated protein-based vaccine based on new guidance.

Vaccines and Related Biological Products Advisory Committee (VRBPAC) members voted unanimously in favor of “harmonizing” Covid vaccine compositions, meaning all future vaccine recipients would receive a bivalent vaccine, regardless of whether they’ve gotten their primary series.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 157,500+ biopharma pros reading Endpoints daily — and it's free.

Healthcare professionals give pharma company engagements middle-of-the-road reviews in a new survey. (Image: Shutterstock)

UCB, No­vo Nordisk, Gilead rank high­est among phar­mas for HCP cus­tomer ex­pe­ri­ence — sur­vey

When it comes to customer service to healthcare professionals, pharma companies’ overall average rating is, well, average. Its industry customer experience score of 59 is at the lower end of “good” (rated as scores from 51-75) in DT Consulting’s annual assessment out now.

Topping the list of individual pharma companies was UCB with a 66 score on the consultant’s proprietary “Customer Experience Quotient” or CXQ scale. Novo Nordisk and Gilead Sciences followed, tied for second at 65, while Boehringer Ingelheim and Johnson & Johnson’s Janssen tied for third with 64. Still, none of the top scores neared “excellent” territory of 76 or higher.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 157,500+ biopharma pros reading Endpoints daily — and it's free.

CBER Director Peter Marks (Susan Walsh/AP Images)

FDA ad­vi­so­ry com­mit­tee votes unan­i­mous­ly in fa­vor of bi­va­lent Covid shots re­plac­ing pri­ma­ry se­ries

The FDA’s Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted unanimously in favor of “harmonizing” Covid vaccine compositions, meaning all current vaccine recipients would receive a bivalent vaccine, regardless of whether they’ve gotten their primary series.

The vote marks an effort to clear up confusion around varying formulations and dosing schedules for current primary series and booster vaccines, as well as “get closer to the strains that are circulating,” according to committee member Paul Offit, professor of pediatrics at the Children’s Hospital of Philadelphia.

FDA re­ports ini­tial 'no sig­nal' for stroke risk with Pfiz­er boost­ers, launch­es con­comi­tant flu shot study

The FDA hasn’t detected any potential safety signals, including for stroke, in people aged 65 years and older who have received Pfizer’s bivalent Covid booster, one senior official told members of the agency’s Vaccines and Related Biological Products Advisory Committee (VRBPAC) on Thursday.

The update comes as the FDA and CDC investigate a “preliminary signal” that may indicate an increased risk of ischemic stroke in older Americans who received Pfizer’s updated shot.

FDA cuts off use for As­traZeneca’s Covid-19 ther­a­py Evusheld

The FDA has stopped use of another drug as a result of the new coronavirus variants. On Thursday, the agency announced that AstraZeneca’s antibody combo Evusheld, which was an important prevention option for many immunocompromised people and others, is no longer authorized.

The FDA said it made its decision based on the fact that Evusheld works on fewer than 10% of circulating variants.

Evusheld was initially given emergency authorization at the end of 2021. However, as Omicron emerged, so did studies that showed Evusheld might not work against the dominant Omicron strain. In October, the FDA warned healthcare providers that Evusheld was useless against the Omicron subvariant BA.4.6. It followed that up with another announcement earlier this month that it did not think Evusheld would work against the latest Omicron subvariant XBB.1.5.

Rodney Rietze, iVexSol CEO

Bris­tol My­ers, Charles Riv­er join Se­ries A fund­ing for iVex­Sol

Massachusetts-based iVexSol has secured funding to the tune of $23.8 million in its latest Series A round. The new investors include Bristol Myers Squibb, manufacturer Charles River Laboratories and Asahi Kasei Medical.

iVexSol is a manufacturer of lentiviral vectors (LVV), used in making gene therapies, and this latest round of fundraising brings its total Series A total over $39 million, which will be used to recruit more employees and bolster its technology.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 157,500+ biopharma pros reading Endpoints daily — and it's free.